Autolus Q1 Revenue Jumps to $26.2M, Achieves Positive Gross Margin
summarizeSummary
Autolus Therapeutics reported strong first-quarter 2026 financial results, with net product revenue surging to $26.2 million, a significant increase from $9.0 million in the prior year, and achieved a positive gross margin. This marks a notable improvement from the increased net losses and reduced cash reserves reported in its 2025 10-K. The company also provided updates on its pipeline, including an RMAT designation for obe-cel in pediatric r/r B-ALL and progress in multiple Phase 2 and Phase 1 trials. Additionally, Autolus detailed its previously announced strategic initiative, including a 13% workforce reduction expected to generate $15 million in annual operating expense savings starting in 2027, alongside $8 million in restructuring charges. These financial and operational improvements are material for the company, indicating positive momentum in its commercialization efforts and pipeline development. Investors will be watching for continued AUCATZYL market expansion and upcoming clinical data readouts.
At the time of this announcement, AUTL was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $455.1M. The 52-week trading range was $1.18 to $2.70. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.